Literature DB >> 15690958

Use of a novel virus inactivation method for a multicenter avian influenza real-time reverse transcriptase-polymerase chain reaction proficiency study.

Erica Spackman1, David L Suarez.   

Abstract

Proficiency assessments are important elements in quality control for diagnostic laboratories. Traditionally, proficiency testing for polymerase chain reaction (PCR)-based assays has involved the use of clinical samples, samples "spiked" with live agents or DNA plasmids. Because of government regulations and biosecurity concerns, distribution of live high-consequence pathogens of livestock and poultry, such as avian influenza, is not possible, and DNA plasmids are not technically suitable for evaluating RNA virus detection. Therefore, a proficiency testing panel using whole avian influenza in a diluent containing a phenolic disinfectant that inactivates the virus while preserving the RNA for at least 8 weeks at -70 C was developed and used in a multicenter proficiency assessment for a type A influenza real-time reverse transcriptase (RT)-PCR test. The test, which was highly standardized, except for variation in the real-time RT-PCR equipment used, was shown to be highly reproducible by proficiency testing in 12 laboratories in the United States, Canada, and Hong Kong. Variation in cycle threshold values among 35 data sets and 490 samples was minimal (CV = 5.19%), and sample identifications were highly accurate (96.7% correct identifications) regardless of real-time PCR instrumentation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690958     DOI: 10.1177/104063870501700117

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  7 in total

1.  Armored RNA as virus surrogate in a real-time reverse transcriptase PCR assay proficiency panel.

Authors:  S K Hietala; B M Crossley
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Ring test evaluation of the detection of influenza A virus in swine oral fluids by real-time reverse-transcription polymerase chain reaction and virus isolation.

Authors:  Christa K Goodell; Jianqiang Zhang; Erin Strait; Karen Harmon; Devi Patnayak; Tracy Otterson; Marie Culhane; Jane Christopher-Hennings; Travis Clement; Pamela Leslie-Steen; Richard Hesse; Joe Anderson; Kevin Skarbek; Amy Vincent; Pravina Kitikoon; Sabrina Swenson; Melinda Jenkins-Moore; Jodi McGill; Rolf Rauh; William Nelson; Catherine O'Connell; Rohan Shah; Chong Wang; Rodger Main; Jeffrey J Zimmerman
Journal:  Can J Vet Res       Date:  2016-01       Impact factor: 1.310

3.  A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus.

Authors:  John Steel; Svetlana V Burmakina; Colleen Thomas; Erica Spackman; Adolfo García-Sastre; David E Swayne; Peter Palese
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

4.  Successes and Short Comings in Four Years of an International External Quality Assurance Program for Animal Influenza Surveillance.

Authors:  Erica Spackman; Carol Cardona; Jeannette Muñoz-Aguayo; Susan Fleming
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

5.  Absence of clinical disease and contact transmission of HPAI H5NX clade 2.3.4.4 from North America in experimentally infected pigs.

Authors:  Bryan S Kaplan; Mia K Torchetti; Kelly M Lager; Richard J Webby; Amy L Vincent
Journal:  Influenza Other Respir Viruses       Date:  2017-09-02       Impact factor: 4.380

6.  Effects of disinfection on the molecular detection of porcine epidemic diarrhea virus.

Authors:  Andrew S Bowman; Jacqueline M Nolting; Sarah W Nelson; Nola Bliss; Jason W Stull; Qiuhong Wang; Christopher Premanandan
Journal:  Vet Microbiol       Date:  2015-06-04       Impact factor: 3.293

7.  Susceptibility of swine to H5 and H7 low pathogenic avian influenza viruses.

Authors:  Charles Balzli; Kelly Lager; Amy Vincent; Phillip Gauger; Susan Brockmeier; Laura Miller; Juergen A Richt; Wenjun Ma; David Suarez; David E Swayne
Journal:  Influenza Other Respir Viruses       Date:  2016-04-05       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.